These results demonstrate that immunomodulation in CLL does not affect TCR signaling or effector differentiation, but mainly cytotoxic responses and cellular trafficking of EBV-specific CD8+ T cells. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.